Tacit Therapeutics emerges from stealth with $19M to develop RNA trans-splicing therapies for brain diseases. Read our feature in Endpoints News.
side

News

Learn more in our latest news about Tacit Therapeutics’ innovative RNA trans-splicing approach advancing next-generation gene therapies for treating complex diseases.
Group 23691

Int he News

EndpointsNews

March 9, 2026

Exclusive: RNA editing startup Tacit Therapeutics launches with $19M for brain diseases

Learn More

Press Release

March 9, 2026

Tacit Therapeutics Announces Series A Financing to Advance RNA Trans-Splicing Medicines for Inherited Diseases

Learn More

Come build with us.

Contact Us
Mask Group 11

Contact